COMMUNIQUÉS West-GlobeNewswire

New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
Children’s National ranked top hospital in the nation by U.S. News & World Report
07/10/2025
Washington, DC, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Children’s National Hospital once again ranked among the nation’s best by U.S. News & World Report Ranked in all specialties, with top 10 honors in neurology and [...]
Scottish Rite for Children Ranked No. 1 for Pediatric Orthopedic Care by U.S. News & World Report
07/10/2025
Hospital has been recognized as one of the nation’s premier centers for 17 years Dallas, Oct. 07, 2025 (GLOBE NEWSWIRE) -- U.S. News & World Report ranked No. 1 in the nation for pediatric orthopedic care in its [...]
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
07/10/2025
Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior chronic therapy Data underscore potential to set new standard-of-care [...]
Carlsbad Dental Care Expands Access to Modern Dentistry with New Patient Special and Financing Options
07/10/2025
Carlsbad, CA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Carlsbad Dental Care, a trusted local practice led by Dr. Raymond Ngo, is improving access to high-quality dental care for families across the Carlsbad community with its [...]
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025
Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine synovial fluid in [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
07/10/2025
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall [...]
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
07/10/2025
Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, [...]
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
07/10/2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil [...]
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
07/10/2025
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended [...]
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
06/10/2025
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced [...]
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
06/10/2025
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION [...]
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
06/10/2025
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased [...]

Pages